Detail

Keywords

Clinical Medicine; Gynecology; Medical Oncology; Personalized Medicine; Translational Medical Research

Research group(s)

• Translational Gynecology
  Members:
  Thomas Bartl

Research interests

My research focuses on translational biomarker studies in gynecologic cancers with the aim of improving treatment stratification and advancing personalized medicine. A particular emphasis lies on rare malignancies, especially advanced and recurrent mucinous ovarian cancer, where novel therapeutic strategies are urgently needed. I am involved in establishing organoid cultures of rare ovarian tumors as a platform for functional drug repurposing and lead collaborative projects exploring host-related biomarkers, including the potential role of Torque Teno Virus as a predictor of response to immune checkpoint inhibition in gynecologic cancers.

Grants

• Torque Teno Virus (TTV) as a Novel Biomarker for Response to Immune-Checkpoint Inhibitor Therapy in Advanced Gynecologic Cancers (2025)
  Source of Funding: Medical Scientific Fund of the Mayor of the City of Vienna, Vienna Fund for Innovative Interdisciplinary Cancer Research
  Principal Investigator
• A Novel Approach of Defining Therapeutic Targets in an Orphan Disease: Formalin-fixed paraffin-embedded Tumor Tissue and Ascites-derived Cell Pellets as a Promising Source for RNA-Profiling in Mucinous Ovarian Cancer (2021)
  Source of Funding: City of Vienna, Vienna Fund for Innovative Interdisciplinary Cancer Research
  Principal Investigator
• Mucinous Ovarian Cancer in the Era of Personalized Medicine: Definition of Novel Biomarkers Predictive of Therapy Response (2019)
  Source of Funding: City of Vienna, City of Vienna Jubilee Fund
  Principal Investigator

Selected publications

1. Onoprienko, A. (..) Bartl T. et al. 2024 ‘Prognostic role of transcription factorARID1Ain patients with endometrial cancer of no specific molecular profile (NSMP) subtype’, International Journal of Gynecologic Cancer, p. ijgc-2023-005111. Available at: https://doi.org/10.1136/ijgc-2023-005111.
2. Bartl, T. et al. 2023 ‘Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer’, International Journal of Gynecologic Cancer, 33(9), pp. 1419–1426. Available at: https://doi.org/10.1136/ijgc-2023-004360.
3. Bartl, T. et al. 2021. ‘Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients’. Cancers, 13(5), p.1076. doi: 10.3390/cancers13051076
4. Srivastava, A. (..) Bartl T. et al. (2025) ‘Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models’, International Journal of Molecular Sciences, 26(18), p. 8866. Available at: https://doi.org/10.3390/ijms26188866.
5. Bartl T. et al, 2018. ‘Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer’. International Journal of Gynecologic Cancer,. 2018 Nov;28(9):1664-1671. doi: 10.1097/IGC.0000000000001369.